Astrana Health Q2 revenue rises 35% to $654.8 million; profit falls, guidance reiterated
Astrana Health reported second-quarter 2025 results on August 7, 2025. Total revenue rose 35% to $654.8 million, but net income attributable to the company fell to $9.4 million, or $0.19 per diluted share, from $19.2 million, or $0.40, a year earlier. The company reiterated full-year 2025 guidance, which includes the Prospect Health acquisition that closed July 1, 2025.
Key points
- Q2 total revenue of $654.8 million, up 35% from $486.3 million; diluted EPS of $0.19 versus $0.40 a year earlier
- Q2 adjusted EBITDA of $48.1 million versus $47.9 million; adjusted EBITDA margin of 7% versus 10%
- Full-year 2025 guidance reiterated: total revenue of $3.1 billion to $3.3 billion and adjusted EBITDA of $215 million to $225 million
- Prospect Health acquisition closed July 1, 2025, with purchase price reduced to $707.9 million from $745.0 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.